

Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma


Neal Bhatia MD¹, Jonathan Kantor MD², Lawrence Green MD³, Jonathan Weiss MD⁴, Cynthia Willson RN, BSN⁵, Susan Cutler DMD⁵, Jayson Rieger PhD, MBA⁶, David K. Glover ME, PhD⁶, Pamela Rumney RN, CCRC⁵, Gary Goldenberg MD^{5,7}

1. Therapeutics Clinical Research, San Diego, CA 2. Florida Center for Dermatology, St. Augustine, FL 3. Dept. of Dermatology, George Washington University School of Medicine, Washington DC 4. Georgia Dermatology Partners and Gwinnett Clinical Research Center Inc., Snellville, GA 5. Verrica Pharmaceuticals Inc., West Chester, PA 6. PBM Capital Group, Charlottesville, VA 7. Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, NY, NY.

INTRODUCTION

- VP-315 is a de-novo designed, intratumoral injected, chemotherapeutic oncolytic peptide in development for basal cell carcinoma (BCC).
- VP-315 has proven to be effective against a panel of drug resistant cancer cells (including multidrug resistant phenotypes) and activates the adaptive immune system by inducing lysis and immunogenic cell death through release of potent immuno-stimulants and a repertoire of tumor antigens.^{1,2}
- LTX-315 is being developed for BCC as VP-315.

Figure 1. VP-315 induces immunogenic cell death in cancer cells¹



When treated with VP-315, dying cancer cells release DAMPs such as calreticulin, ATP, HMGB1, mtDNA and formyl peptides. DAMPs bind to specific receptors on antigen-presenting cells such as dendritic cells and promotes their maturation and engulfment of tumor-antigens with subsequent presentation to T cells and execution of effective immune response.

DAMP: Damage-associated molecular pattern; FMIT: Mitochondrial N-formyl peptide; mtDNA: Mitochondria-derived DNA.

OBJECTIVES & ENDPOINTS

- The primary objectives of this study were to assess safety, tolerability, and maximum tolerated dose (MTD) of ascending dose strengths of VP-315 as a monotherapy in adult subjects with biopsy proven BCC.
- Primary endpoints of the study included discontinuations due to adverse events (AEs), occurrence of dose-limiting toxicity (DLT), and assessment of expected cutaneous reactions related to treatment at different doses, including lesion necrosis.

METHODS

- This is Part 1 of a 2 part dose-escalation study.
- Part 1: N=10 (total study N=80).
- Subjects received treatment comprised of ascending once daily dosing, up to 3 consecutive treatment days in a 7-day treatment week, followed by no treatment for ≥ 4 days.
- Subjects were treated up to 6 treatments over a 2-week period, in ≤ 2 lesions.

DEMOGRAPHICS

Table 1. Summary of Demographics Baseline Characteristics*


	N	%		N	%		N	%
Gender at birth (N=10)			FST (N=10)			Body Area (N=12)		
Female	5	50	I	3	30	Arm	2	16.7
Male	5	50	II	4	40	Back	6	50
Age (N=10)			III	3	30	Chest	1	8.3
Ranges	51-76		IV	0	0	Clavicle	1	8.3
			V	0	0	Neck	1	8.3
			VI	0	0	Shoulder	1	8.3

* FST=Fitzpatrick Skin Type. Two subjects had 2 lesions treated.

RESULTS

- All 10 subjects completed treatment with VP-315.
- The full target range of doses were well tolerated.
- A maximum dose of 8 mg did not reach a MTD in any subject.
- No subjects experienced DLTs.
- Most treatment-related adverse events (TRAEs) were mild to moderate, and expected.
- Expected cutaneous reactions were observed.
- No treatment-related serious adverse events (SAEs) were reported.

Images pre and post VP-315 Treatment



BCC, received 3 consecutive daily doses of 8 mg VP-315 with full necrosis observed on W1D4.

BCC, received 3 consecutive daily doses of 8 mg VP-315 and full necrosis observed on W2D1.

BCC=Basal Cell Carcinoma; W1D1=Week 1 Day 1; W1D4=Week 1 Day 4; W2D1=Week 2 Day 1.

Table 2. Dose Escalation Scheme by Subject

Subject N=10	# Lesions Treated	Dosage Scheme (mg)	Total # of Treatments	Clinical Necrosis Achieved
1	Lesion 1	2mg, 3mg, 4mg, 5mg, 6mg, 7mg	6	No
2	Lesion 1	3mg, 4mg, 5mg, 6mg, 7mg, 8mg	6	No
3	Lesion 1	4mg, 5mg, 6mg, 7mg, 8mg, 8mg	6	No
4	Lesion 1	5mg, 6mg, 7mg	3	Yes
	Lesion 2	6mg, 7mg, 8mg	3	Yes
5	Lesion 1	7mg, 8mg, 8mg	3	Yes
	Lesion 2	8mg, 8mg, 8mg	3	Yes
6	Lesion 1	8mg, 8mg, 8mg, 8mg	4	Yes
7	Lesion 1	8mg, 8mg, 8mg	3	Yes
8	Lesion 1	8mg, 8mg, 8mg	3	Yes
9	Lesion 1	8mg, 8mg, 8mg	3	Yes
10	Lesion 1	8mg, 8mg, 8mg	3	Yes

CONCLUSIONS

- VP-315 demonstrated a tolerable safety profile.
- Subjects receiving the higher range of dosing experienced a consistent response of clinical tumor necrosis.
- VP-315 warrants continued research as a potential non-surgical immunotherapy for BCC.

References

1. Sveinbjörnsson, Baldur et al. "LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment." *Future Medicinal Chemistry* 9 12 (2017): 1339-1344.
2. Eike LM, Yang N, Rekdal Ø, Sveinbjörnsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. *Oncotarget*. 2015 Oct 27;6(33):34910-23.

Disclosures

The author affiliations are: **N Bhatia**: I, C; **J Kantor**: I; **L Green**: I; **J Weiss**: I, C; **C Willson**: E; **S Cutler**: E; **J Rieger**: C; **D Glover**: C; **P Rumney**: E; **G Goldenberg**: E. (I=clinical trial investigator; C=consultant; E=employee.) This study was sponsored by Verrica Pharmaceuticals Inc. Editorial support was provided by Versant Learning Solutions, Inc, and funded by Verrica Pharmaceuticals Inc.